tbuckley/cabot-search huggingface dataset:
Quality of Life and Patient Satisfaction After Antibiotic Therapy vs Appendectomy for Uncomplicated Appendicitis—Reply
Authors: Suvi Sippola, Jussi Haijanen, Paulina Salminen
Journal: JAMA Surgery (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
The Pathognomonic FOXL2 C134W Mutation Alters DNA-Binding Specificity
Authors: Annaïck Carles, Genny Trigo-Gonzalez, Qi Cao, S.-W. Grace Cheng, Michelle Moksa, Misha Bilenky, David G. Huntsman, Gregg B. Morin, Martin Hirst
Journal: Cancer Research (2020)

The somatic missense point mutation c.402C>G (p.C134W) in the FOXL2 transcription factor is pathognomonic for adult-type granulosa cell tumors (AGCT) and a diagnostic marker for this tumor type. However, the molecular consequences of this mutation and its contribution to the mechanisms of AGCT pathogenesis remain unclear. To explore these mechanisms, we engineered V5-FOXL2WT- and V5-FOXL2C134W-inducible isogenic cell lines and performed chromatin immunoprecipitation sequencing and transcriptome profiling. FOXL2C134W associated with the majority of the FOXL2 wild-type DNA elements as well as a large collection of unique elements genome wide. This model enabled confirmation of altered DNA-binding specificity for FOXL2C134W and identification of unique targets of FOXL2C134W including SLC35F2, whose expression increased sensitivity to YM155. Our results suggest FOXL2C134W drives AGCT by altering the binding affinity of FOXL2-containing complexes to engage an oncogenic transcriptional program. SIGNIFICANCE: A mechanistic understanding of FOXL2C134W-induced regulatory state alterations drives discovery of a rationally designed therapeutic strategy.
Defining the endoscopic ultrasound features of chronic pancreatitis in Asians: a multicenter validation study
Authors: Calvin Jianyi Koh, Sundeep Lakhtakia, Mitsuhiro Kida, Cosmas Rinaldi A. Lesmana, Tiing Leong Ang, Charles Kieng Fong Vu, Than Than Aye, Sun Hwa Park, Majid A. Almadi, Charing Ching-Ning Chong, Raymond Shing Yan Tang, Xi Wu, Ida Hilmi, Vinay Dhir, Nonthalee Pausawasdi, Jahangeer Basha, Zhen-Dong Jin, Ai Ming Yang, Anthony Yuen Bun Teoh, Dong-Wan Seo, Hsiu-Po Wang, Khek Yu Ho
Journal: Endoscopy (2020)

Background Although endoscopic ultrasound (EUS) features and criteria have been described in chronic pancreatitis, challenges remain with interoperator variability and ease of adoption. The aim of this study was to define and validate the EUS features of chronic pancreatitis in a multicenter prospective study in Asia. Method The study was divided into two parts: the first part was conducted to derive the EUS features of chronic pancreatitis with adequate interoperator agreement; the second was to prospectively evaluate these features in a multicenter cross-sectional study and determine the optimal combination of features for the diagnosis of chronic pancreatitis. Prospectively enrolled cases had standard internationally validated radiologic or histologic features of chronic pancreatitis, and controls were patients without chronic pancreatitis who underwent EUS examination. Results The top six EUS features that had good interobserver agreement (mean kappa 0.73, range 0.60 – 0.90) were selected to be further evaluated in part II of the study. These included: hyperechoic foci with shadowing, lobularity with honeycombing, cysts, dilated main pancreatic duct, dilated side branches, and calculi in the main pancreatic duct. A total of 284 subjects (132 cases, 152 controls) were enrolled from 12 centers in Asia. All six features had high accuracy ranging from 63.3 % to 89.1 %. Two or more of these six EUS features accurately defined chronic pancreatitis (sensitivity 94.7 %, specificity 98.0 %), with an area under the receiver operating curve of 0.986. Conclusion This multicenter Asian study characterized and defined the EUS features of chronic pancreatitis. This provides a useful tool in clinical practice and further research in pancreatic cancer surveillance.
SO-3 Maintenance olaparib in patients aged ≥65 years with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial
Authors: H. Kindler, P. Hammel, M. Reni, E. Van Cutsem, T. Macarulla, M. Hall, J. Park, D. Hochhauser, D. Arnold, D. Oh, A. Reinacher-Schick, G. Tortora, H. Algül, E. O'Reilly, D. McGuinness, K. Cui, K. Schlienger, G. Locker, T. Golan
Journal: Annals of Oncology (2020)
Fetal Origins of Asthma: A Longitudinal Study from Birth to Age 36 Years
Authors: Stefano Guerra, Enrico Lombardi, Debra A. Stern, Duane L. Sherrill, Dorothy Gilbertson-Dahdal, Courtney M. Wheatley-Guy, Eric M. Snyder, Anne L. Wright, Fernando D. Martinez, Wayne J. Morgan
Journal: American Journal of Respiratory and Critical Care Medicine (2020)

Deficits in infant lung function-including the ratio of the time to reach peak tidal expiratory flow to the total expiratory time (tptef/te) and maximal expiratory flow at FRC (V̇maxFRC)-have been linked to increased risk for childhood asthma.
Antibody-mediated inhibition of GDF15–GFRAL activity reverses cancer cachexia in mice
Authors: Rowena Suriben, Michael Chen, Jared Higbee, Julie Oeffinger, Richard Ventura, Betty Li, Kalyani Mondal, Zhengyu Gao, Dina Ayupova, Pranali Taskar, Diana Li, Shelley R. Starck, Hung-I Harry Chen, Michele McEntee, Subhash D. Katewa, Van Phung, Marilyn Wang, Avantika Kekatpure, Damodharan Lakshminarasimhan, Andre White, Andrea Olland, Raj Haldankar, Mark J. Solloway, Jer-Yuan Hsu, Yan Wang, Jie Tang, Darrin A. Lindhout, Bernard B. Allan
Journal: Nature Medicine (2020)
Tape strips from early‐onset pediatric atopic dermatitis highlight disease abnormalities in nonlesional skin
Authors: Ana B. Pavel, Yael Renert‐Yuval, Jianni Wu, Ester Del Duca, Aisleen Diaz, Rachel Lefferdink, Milie M. Fang, Talia Canter, Stephanie M. Rangel, Ning Zhang, James G. Krueger, Amy S. Paller, Emma Guttman‐Yassky
Journal: Allergy (2020)

Skin biopsies promote our understanding of atopic dermatitis/AD pathomechanisms in infants/toddlers with early-onset AD, but are not feasible in pediatric populations. Tape strips are an emerging, minimally invasive alternative, but global transcriptomic profiling in early pediatric AD is lacking. We aimed to provide global lesional and nonlesional skin profiles of infants/toddlers with recent-onset, moderate-to-severe AD using tape strips.Sixteen tape strips were collected for RNA-seq profiling from 19 infants/toddlers (<5 years old; lesional and nonlesional) with early-onset moderate-to-severe AD (≤6 months) and 17 healthy controls.We identified 1829 differentially expressed genes/DEGs in lesional AD and 662 DEGs in nonlesional AD, vs healthy skin (fold-change ≥2, FDR <0.05), with 100% sample recovery. Both lesional and nonlesional skin showed significant dysregulations of Th2 (CCL17 and IL4R) and Th22/Th17 (IL36G, CCL20, and S100As)-related genes, largely lacking significant Th1-skewing. Significant down-regulation of terminal differentiation (FLG and FLG2), lipid synthesis/metabolism (ELOVL3 and FA2H), and tight junction (CLDN8) genes were primarily seen in lesional AD. Significant negative correlations were identified between Th2 measures and epidermal barrier gene-subsets and individual genes (FLG with IL-4R and CCL17; r < -0.4, P < .05). Significant correlations were also identified between clinical measures (body surface area/BSA, pruritus ADQ, and transepidermal water loss/TEWL) with immune and barrier mRNAs in lesional and/or nonlesional AD (FLG/FLG2 with TEWL; r < -0.4, P < .05).RNA-seq profiling using tape strips in early-onset pediatric AD captures immune and barrier alterations in both lesional and nonlesional skin. Tape strips provide insight into disease pathomechanisms and cutaneous disease activity.
Abstract 12268: Efficacy of Bempedoic Acid: A Pooled Analysis of 4 Pivotal Phase 3 Clinical Trials
Authors: Maciej Banach, P. Barton Duell, Antonio Gotto, Ulrich Laufs, Lawrence A Leiter, G. B. J Mancini, Kausik K Ray, JoAnn Flaim, Zhan Ye, Alberico L Catapano
Journal: Circulation (2019)

Introduction: Bempedoic acid (BA), a first-in-class, oral, small-molecule, ATP-citrate lyase (ACL) inhibitor, lowers low-density lipoprotein cholesterol (LDL-C) in patients with hyperlipidemia. Her...
Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities
Authors: Giovanni Quarta, Mauro Gori, Annamaria Iorio, Emilia D'Elia, James C. Moon, Attilio Iacovoni, Simone Burocchi, Erik B. Schelbert, Paolo Brambilla, Sandro Sironi, Sergio Caravita, Gianfranco Parati, Antonello Gavazzi, Alan S. Maisel, Javed Butler, Carolyn S.P. Lam, Michele Senni
Journal: European Journal of Heart Failure (2020)
Rising to the triple challenge of covid-19, Brexit, and climate change
Authors: Liz Green, Sara Wood, Mark A Bellis
Journal: BMJ (2020)

Anderson and colleagues discuss the need to mitigate the longer term effects of the covid-19 pandemic in an equitable way.1 Plans for the United Kingdom need to tackle the triple public health challenge it faces from covid-19, climate change, and Brexit.

The pandemic and measures to control it are exposing interwoven relationships between wellbeing, inequalities, the economy, the environment, and society as …
Genome-wide analysis of high-risk primary brain cancer pedigrees identifies <i>PDXDC1</i> as a candidate brain cancer predisposition gene
Authors: Lisa A Cannon-Albright, James M Farnham, Jeffrey Stevens, Craig C Teerlink, Cheryl A Palmer, Kerry Rowe, Melissa H Cessna, Deborah T Blumenthal
Journal: Neuro-Oncology (2020)

There is evidence for an inherited contribution to primary brain cancer. Linkage analysis of high-risk brain cancer pedigrees has identified candidate regions of interest in which brain cancer predisposition genes are likely to reside.Genome-wide linkage analysis was performed in a unique set of 11 informative, extended, high-risk primary brain cancer pedigrees identified in a population genealogy database, which include from 2 to 6 sampled, related primary brain cancer cases. Access to formalin-fixed paraffin embedded tissue samples archived in a biorepository allowed analysis of extended pedigrees.Individual high-risk pedigrees were singly informative for linkage at multiple regions. Suggestive evidence for linkage was observed on chromosomes 2, 3, 14, and 16. The chromosome 16 region in particular contains a promising candidate gene, pyridoxal-dependent decarboxylase domain-containing 1 (PDXDC1), with prior evidence for involvement with glioblastoma from other previously reported experimental settings, and contains the lead single nucleotide polymorphism (rs3198697) from the linkage analysis of the chromosome 16 region.Pedigrees with a statistical excess of primary brain cancers have been identified in a unique genealogy resource representing the homogeneous Utah population. Genome-wide linkage analysis of these pedigrees has identified a potential candidate predisposition gene, as well as multiple candidate regions that could harbor predisposition loci, and for which further analysis is suggested.
SO-8 Safety, tolerability, and efficacy of transarterial chemoembolization using anthracyclines-loaded drug-eluting microspheres for treatment of patients with unresectable hepatocellular carcinoma: Pooled analyses
Authors: T. De Baere, F. Veloso Gomes, T. Gerardo, K. Malagari, G. Verset, J. Bruix
Journal: Annals of Oncology (2020)
Influence of Cell Membrane Wrapping on the Cell−Porous Silicon Nanoparticle Interactions
Authors: Flavia Fontana, Hanna Lindstedt, Alexandra Correia, Jacopo Chiaro, Otto K. Kari, Joseph Ndika, Harri Alenius, Jonas Buck, Sandro Sieber, Ermei Mäkilä, Jarno Salonen, Arto Urtti, Vincenzo Cerullo, Jouni T. Hirvonen, Hélder A. Santos
Journal: Advanced Healthcare Materials (2020)

Abstract Biohybrid nanosystems represent the cutting‐edge research in biofunctionalization of micro‐ and nano‐systems. Their physicochemical properties bring along advantages in the circulation time, camouflaging from the phagocytes, and novel antigens. This is partially a result of the qualitative differences in the protein corona, and the preferential targeting and uptake in homologous cells. However, the effect of the cell membrane on the cellular endocytosis mechanisms and time has not been fully evaluated yet. Here, the effect is assessed by quantitative flow cytometry analysis on the endocytosis of hydrophilic, negatively charged porous silicon nanoparticles and on their membrane‐coated counterparts, in the presence of chemical inhibitors of different uptake pathways. Principal component analysis is used to analyze all the data and extrapolate patterns to highlight the cell‐specific differences in the endocytosis mechanisms. Furthermore, the differences in the composition of static protein corona between naked and coated particles are investigated together with how these differences affect the interaction with human macrophages. Overall, the presence of the cell membrane only influences the speed and the entity of nanoparticles association with the cells, while there is no direct effect on the endocytosis pathways, composition of protein corona, or any reduction in macrophage‐mediated uptake.
Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
Authors: Adam Pennycuick, Vitor H. Teixeira, Khalid AbdulJabbar, Shan E. Ahmed Raza, Tom Lund, Ayse U. Akarca, Rachel Rosenthal, Lukas Kalinke, Deepak P. Chandrasekharan, Christodoulos P. Pipinikas, Henry Lee-Six, Robert E. Hynds, Kate H.C. Gowers, Jake Y. Henry, Fraser R. Millar, Yeman B. Hagos, Celine Denais, Mary Falzon, David A. Moore, Sophia Antoniou, Pascal F. Durrenberger, Andrew J. Furness, Bernadette Carroll, Claire Marceaux, Marie-Liesse Asselin-Labat, William Larson, Courtney Betts, Lisa M. Coussens, Ricky M. Thakrar, Jeremy George, Charles Swanton, Christina Thirlwell, Peter J. Campbell, Teresa Marafioti, Yinyin Yuan, Sergio A. Quezada, Nicholas McGranahan, Sam M. Janes
Journal: Cancer Discovery (2020)

Abstract Before squamous cell lung cancer develops, precancerous lesions can be found in the airways. From longitudinal monitoring, we know that only half of such lesions become cancer, whereas a third spontaneously regress. Although recent studies have described the presence of an active immune response in high-grade lesions, the mechanisms underpinning clinical regression of precancerous lesions remain unknown. Here, we show that host immune surveillance is strongly implicated in lesion regression. Using bronchoscopic biopsies from human subjects, we find that regressive carcinoma in situ lesions harbor more infiltrating immune cells than those that progress to cancer. Moreover, molecular profiling of these lesions identifies potential immune escape mechanisms specifically in those that progress to cancer: antigen presentation is impaired by genomic and epigenetic changes, CCL27–CCR10 signaling is upregulated, and the immunomodulator TNFSF9 is downregulated. Changes appear intrinsic to the carcinoma in situ lesions, as the adjacent stroma of progressive and regressive lesions are transcriptomically similar. Significance: Immune evasion is a hallmark of cancer. For the first time, this study identifies mechanisms by which precancerous lesions evade immune detection during the earliest stages of carcinogenesis and forms a basis for new therapeutic strategies that treat or prevent early-stage lung cancer. See related commentary by Krysan et al., p. 1442. This article is highlighted in the In This Issue feature, p. 1426
Increase in Incidence of Neonatal Abstinence Syndrome Among In-Hospital Birth in the United States
Authors: Kamleshun Ramphul, Stephanie Gonzalez Mejias, Jyotsnav Joynauth
Journal: JAMA Pediatrics (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Methotrexate and rheumatoid arthritis associated interstitial lung disease
Authors: Pierre-Antoine Juge, Joyce S. Lee, Jessica Lau, Leticia Kawano-Dourado, Jorge Rojas Serrano, Marco Sebastiani, Gouri Koduri, Eric Matteson, Karina Bonfiglioli, Marcio Sawamura, Ronaldo Kairalla, Lorenzo Cavagna, Emanuele Bozzalla Cassione, Andreina Manfredi, Mayra Mejia, Pedro Rodríguez-Henriquez, Montserrat I. González-Pérez, Ramcés Falfán-Valencia, Ivette Buendia-Roldán, Gloria Pérez-Rubio, Esther Ebstein, Steven Gazal, Raphaël Borie, Sébastien Ottaviani, Caroline Kannengiesser, Benoît Wallaert, Yurdagul Uzunhan, Hilario Nunes, Dominique Valeyre, Nathalie Saidenberg-Kermanac'h, Marie-Christophe Boissier, Lidwine Wemeau-Stervinou, René-Marc Flipo, Sylvain Marchand-Adam, Pascal Richette, Yannick Allanore, Claire Dromer, Marie-Elise Truchetet, Christophe Richez, Thierry Schaeverbeke, Huguette Lioté, Gabriel Thabut, Kevin D. Deane, Joshua J. Solomon, Tracy Doyle, Jay H. Ryu, Ivan Rosas, V. Michael Holers, Catherine Boileau, Marie-Pierre Debray, Raphaël Porcher, David A. Schwartz, Robert Vassallo, Bruno Crestani, Philippe Dieudé
Journal: European Respiratory Journal (2020)

Methotrexate (MTX) is a key anchor drug for rheumatoid arthritis (RA) management. Fibrotic interstitial lung disease (ILD) is a common complication of RA. Whether MTX exposure increases the risk of ILD in patients with RA is disputed. We aimed to evaluate the association of prior MTX use with development of RA-ILD.Through a case-control study design with discovery and international replication samples, we examined the association of MTX exposure with ILD in 410 patients with chronic fibrotic ILD associated with RA (RA-ILD) and 673 patients with RA without ILD. Estimates were pooled over the different samples using meta-analysis techniques.Analysis of the discovery sample revealed an inverse relationship between MTX exposure and RA-ILD (adjusted OR 0.46, 95% CI 0.24-0.90; p=0.022), which was confirmed in the replication samples (pooled adjusted OR 0.39, 95% CI 0.19-0.79; p=0.009). The combined estimate using both the derivation and validation samples revealed an adjusted OR of 0.43 (95% CI 0.26-0.69; p=0.0006). MTX ever-users were less frequent among patients with RA-ILD compared to those without ILD, irrespective of chest high-resolution computed tomography pattern. In patients with RA-ILD, ILD detection was significantly delayed in MTX ever-users compared to never-users (11.4±10.4 years and 4.0±7.4 years, respectively; p<0.001).Our results suggest that MTX use is not associated with an increased risk of RA-ILD in patients with RA, and that ILD was detected later in MTX-treated patients.
Positron Emission Tomography–Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001
Authors: Daniel O. Persky, Hongli Li, Deborah M. Stephens, Steven I. Park, Nancy L. Bartlett, Lode J. Swinnen, Paul M. Barr, Jerome D. Winegarden, Louis S. Constine, Thomas J. Fitzgerald, John P. Leonard, Brad S. Kahl, Michael L. LeBlanc, Joo Y. Song, Richard I. Fisher, Lisa M. Rimsza, Sonali M. Smith, Thomas P. Miller, Jonathan W. Friedberg
Journal: Journal of Clinical Oncology (2020)

Diffuse large B-cell lymphoma (DLBCL) presents as a limited-stage disease in 25% to 30% of patients, with better overall survival (OS) than that for advanced-stage disease but with continuous relapse regardless of treatment approach. The preferred treatment is abbreviated rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and radiation therapy. On the basis of promising results of positron emission tomography (PET)-directed treatment approaches, we designed a National Clinical Trials Network (NCTN) study to improve outcomes and decrease toxicity.Patients with nonbulky (< 10 cm) stage I/II untreated DLBCL received 3 cycles of standard R-CHOP therapy and underwent a centrally reviewed interim PET/computed tomography scan (iPET). Those with a negative iPET proceeded with 1 additional cycle of R-CHOP, whereas those with a positive iPET received involved field radiation therapy followed by ibritumomab tiuxetan radioimmunotherapy.Of 158 patients enrolled, 132 were eligible and 128 underwent iPET, which was positive in 14 (11%) of the patients. With a median follow-up of 4.92 years (range, 1.1-7.7 years), only 6 patients progressed and 3 died as a result of lymphoma. Eleven patients died as a result of nonlymphoma causes at a median age of 80 years. The 5-year progression-free survival estimate was 87% (95% CI, 79% to 92%) and the OS estimate was 89% (95% CI, 82% to 94%), with iPET-positive and iPET-negative patients having similar outcomes.To our knowledge, S1001 is the largest prospective study in the United States of limited-stage DLBCL in the rituximab era, with the best NCTN results in this disease subset. With PET-directed therapy, 89% of the patients with a negative iPET received R-CHOP × 4, and only 11% had a positive iPET and required radiation, with both groups having excellent outcomes. The trial establishes R-CHOP × 4 alone as the new standard approach to limited-stage disease for the absolute majority of patients.
Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome
Authors: Manish A. Shah, Peter Enzinger, Andrew H. Ko, Allyson J. Ocean, Philip Agop Philip, Prashant V. Thakkar, Kyle Cleveland, Yao Lu, Jeremy Kortmansky, Paul J. Christos, Chao Zhang, Navjot Kaur, Dina Elmonshed, Giuseppe Galletti, Sandipto Sarkar, Bhavneet Bhinder, Meredith E. Pittman, Olga Mikhaylovna Plotnikova, Nikita Kotlov, Felix Frenkel, Aleksander Bagaev, Olivier Elemento, Doron Betel, Paraskevi Giannakakou, Heinz-Josef Lenz
Journal: Clinical Cancer Research (2020)

We examined cabazitaxel, a novel next-generation taxoid, in patients with metastatic gastric cancer in a multicenter phase II study.